All right. Thank you.
Just changing gears here, we've talked about our commitment to pharmacare. As you well know, that's something I've been quite involved in. I believe it is an important issue. I'm looking forward to Dr. Hoskins' report.
As you might guess, there is some opposition from certain players with financial interests in the status quo in our pharmaceutical coverage system. One of them involves our initiatives to control drug prices. There are claims from industry that if we lower the price Canada pays for its drugs, this will decrease investment in research, decrease the development of new drugs and put the safety of Canadians at risk.
Could you respond to the veracity of this claim?